The International Waldenstrom’s Macroglobulinemia Foundation (IWMF)
The International Waldenstrom’s Macroglobulinemia Foundation (IWMF) is a patient-founded and patient-led non-profit organization, comprised of 99% volunteers and represents 32,000 Waldenstrom’s patients worldwide! They want you to know with the IWMF, you are never alone and anyone can become a member. As the IWMF strives to support the lives of those living with this rare cancer, the organization offers critical services to achieve that end.
Condition Awareness & Advocacy
Here is a list of conditions this partner raises awareness and advocacy for:
Resources & Support
Patient Worthy Posts on Waldenstrom Macroglobulinemia
Saturday Afternoon Live: Dr. Steven Treon’s Presentation at the 2019 IWMF Educational Forum June 8th will be Streamed Online!
The International Waldenstrom’s Macroglobulinemia Foundation (IWMF) is a nonprofit organization founded by patients. Their mission? Support patients currently living with Waldenstrom’s Macroglobulinemia (WM) while simultaneously
Research Updates for Multiple Myeloma and WM!
Dana-Farber Cancer Institute has just announced research updates on multiple myeloma and waldenstrom macroglobulinemia which indicate significant progress in the search for treatments for these
First Chemotherapy-Free Combination Treatment Approved For Waldrenstrom’s Macroglobulinemia
According to a story from BioSpace, the biopharmaceutical company AbbVie recently announced that the US Food and Drug Administration (FDA) has approved a new combination
A Patient With Waldenström Macroglobulinemia has Shown a Large Reduction in Overall Tumour Volume While Taking Part in a Clinical Trial
A patient with Waldenström Macroglobulinemia taking part in a clinical trial of the experimental drug CLR 131 for the treatment of B-cell hematologic cancers is
A Supplemental New Drug Application Has Been Submitted For a Combination Therapy For Waldenström Macroglobulinemia
The US Food and Drug Administration (FDA) is reviewing a supplemental New Drug Application (sNDA) for the drug Imbruvica (ibrutinib) in combination with rituximab (Rituxan)
Get Connected! Waldenstrom Macroglobulinemia (WM) Support Groups
There is support out there for people living with and/or affected by Waldenstrom macroglobulinemia (WM). Thankfully, according to Patient Worthy Partner International Waldenstrom’s Macroglobulinemia Foundation (IWMF,)
